Karim Azad S, Son Andre Y, Suen Rachel, Walter James M, Saine Mark, Kim Samuel S, Odell David D, Thakkar Sanket, Kurihara Chitaru, Bharat Ankit
Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
J Extra Corpor Technol. 2020 Mar;52(1):52-57. doi: 10.1182/JECT-1900035.
Veno-venous extracorporeal membrane oxygenation (VV-ECMO) has emerged as a potential life-saving treatment for patients with acute respiratory failure. Given the accumulating literature supporting the use of VV-ECMO without therapeutic levels of anticoagulation, it might be feasible to use it for planned intubation before surgical procedures. Here, we report consecutive series of patients who underwent planned initiation of VV-ECMO, without anticoagulation, before induction of general anesthesia for anticipated difficult airways or respiratory decompensation. We describe the approach to safely initiate VV-ECMO in an awake patient. We retrospectively identified patients in a prospectively maintained database who underwent planned initiation of VV-ECMO before intubation. Standard statistical methods were used to determine post-procedure outcomes. Patients included were three men and one woman, with a mean age of 34.3 ± 10.4 years. Indications included mediastinal lymphoma, foreign body obstruction, hemoptysis, and tracheo-esophageal fistula. VV-ECMO was initiated electively for all patients, and no anticoagulation was used. The median duration of VV-ECMO support was 2.5 days (1-11 days), the median length of ventilator dependence and intensive care unit stay was 1 day (1-23 days) and 5 days (4-31 days), respectively. The median length of stay was 18.5 days (8-39 days). There were no thrombotic complications and no mortality at 30 days. Initiation of awake VV-ECMO is feasible and is safe before intubation and induction of anesthesia in patients at high risk for respiratory decompensation.
静脉-静脉体外膜肺氧合(VV-ECMO)已成为治疗急性呼吸衰竭患者的一种潜在的挽救生命的疗法。鉴于越来越多的文献支持在未达到治疗性抗凝水平的情况下使用VV-ECMO,在手术前将其用于计划性插管可能是可行的。在此,我们报告了一系列连续的患者,他们在预期气道困难或呼吸失代偿的情况下,在全身麻醉诱导前接受了无抗凝的计划性VV-ECMO启动。我们描述了在清醒患者中安全启动VV-ECMO的方法。我们回顾性地在一个前瞻性维护的数据库中识别出在插管前接受计划性VV-ECMO启动的患者。使用标准统计方法确定术后结果。纳入的患者包括3名男性和1名女性,平均年龄为34.3±10.4岁。适应证包括纵隔淋巴瘤、异物阻塞、咯血和气管食管瘘。所有患者均选择性地启动了VV-ECMO,且未使用抗凝剂。VV-ECMO支持的中位持续时间为2.5天(1-11天),呼吸机依赖和重症监护病房停留的中位时间分别为1天(1-23天)和5天(4-31天)。中位住院时间为18.5天(8-39天)。30天内无血栓形成并发症且无死亡病例。对于呼吸失代偿高危患者,在插管和麻醉诱导前启动清醒VV-ECMO是可行且安全的。